CTNNB1
Catenin beta-1
As of the edition of 20 October 2026, CTNNB1 (catenin beta-1, UniProt P35222) has 5 drugs tested at it and 5 companies on the list, 1 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P35222
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 52
- Disease areas
- Cancer; Digestive system; Blood and lymph; Inherited and neonatal; Hormones; Infections; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 23
Drugs at this target
| Status | Count |
|---|---|
| Active | 4 |
| Stopped | 1 |
| Total | 5 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| PRI-724 | Active | Phase 2 | none listed |
| Tegavivint | Active | Phase 2 | none listed |
| CWP232291 | Stopped | Phase 2 | none listed |
| DPTX3186 | Active | Phase 1 | none listed |
| FOG-001 | Active | Phase 2 | none listed |
5 of 5 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Engaged | 3 |
| Undetermined | 1 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| JW Pharmaceutical | Route A |
The other 4 companies at CTNNB1
In the product5 companies in all; 4 are not named here, and no score is.
See the 5 companies at CTNNB1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.